• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

公共卫生幕后故事:不列颠哥伦比亚省免疫接种后不良事件(AEFI)信号调查

Behind the scenes in public health: Adverse events following immunization (AEFI) signal investigation in British Columbia.

作者信息

MacDonald L, Naus M

机构信息

Immunization Programs and Vaccine Preventable Diseases Service, British Columbia Centre for Disease Control, Vancouver, BC.

School of Population and Public Health, University of British Columbia, Vancouver, BC.

出版信息

Can Commun Dis Rep. 2014 Dec 4;40(Suppl 3):24-30. doi: 10.14745/ccdr.v40is3a03.

DOI:10.14745/ccdr.v40is3a03
PMID:29769909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5868569/
Abstract

BACKGROUND

In British Columbia, vaccine safety is monitored through a passive surveillance system with voluntary reporting of adverse events following immunization (AEFIs) from immunizers to five regional health authorities and onward to the British Columbia Centre for Disease Control (BCCDC).

OBJECTIVE

To review and summarize all documented AEFI cluster or signal investigations carried out by BCCDC between November 2007 and July 2014.

METHOD

Documented cluster or signal investigations were reviewed to summarize year, alerting mechanism, event type and vaccine, investigative analysis approach, results, and public health actions. The findings and public health actions of two cluster investigations are described in detail.

RESULTS

There were two fatality investigations and thirteen cluster investigations. The two fatalities were found to be due to sudden infant death syndrome and were not vaccine-related. Clusters were predominantly identified through notification from regional medical health officers or public health nurses, and the majority were local injection site reactions (54%), or allergic events (39%). Most investigations did not identify a specific association to a vaccine or a lot of vaccine, and no public health actions were taken. Two recent investigations-reports of hypotonic-hyporesponsive episodes with or without severe vomiting and diarrhea following receipt of a single lot of DPT-IPV/Hib/hepatitis B vaccine, and reports of severe pain past nearest joint following administration of a single lot of influenza vaccine-were thought to be vaccine-related. The former investigation did not find an association to vaccine, while the severe local reactions post-influenza immunization were determined to be a result of improper injection technique. Public health actions included communication to federal/provincial/territorial vaccine safety partners and additional injection technique training.

CONCLUSION

This investigative aspect of public health immunization programs is often not in the public eye but is an important component of behind the scenes activities that serve to protect public safety.

摘要

背景

在不列颠哥伦比亚省,通过一个被动监测系统对疫苗安全性进行监测,免疫接种人员将免疫接种后出现的不良事件(AEFI)自愿报告给五个地区卫生当局,再上报至不列颠哥伦比亚疾病控制中心(BCCDC)。

目的

回顾并总结BCCDC在2007年11月至2014年7月期间开展的所有已记录的AEFI聚集性事件或信号调查。

方法

对已记录的聚集性事件或信号调查进行回顾,以总结年份、警报机制、事件类型和疫苗、调查分析方法、结果及公共卫生行动。详细描述了两次聚集性事件调查的结果和公共卫生行动。

结果

有两次死亡调查和十三次聚集性事件调查。发现这两起死亡事件是由婴儿猝死综合征导致的,与疫苗无关。聚集性事件主要通过地区医疗卫生官员或公共卫生护士的通报确定,大多数是局部注射部位反应(54%)或过敏事件(39%)。大多数调查未发现与某种疫苗或某一批次疫苗有特定关联,未采取公共卫生行动。最近的两项调查——关于接种一批白百破-脊灰- Hib/乙肝疫苗后出现或未出现严重呕吐和腹泻的低张低反应发作报告,以及接种一批流感疫苗后最近关节处出现严重疼痛的报告——被认为与疫苗有关。前一项调查未发现与疫苗有关联,而流感免疫接种后的严重局部反应被确定是注射技术不当所致。公共卫生行动包括与联邦/省/地区疫苗安全合作伙伴沟通以及提供额外的注射技术培训。

结论

公共卫生免疫计划的这一调查方面通常不为公众所见,但却是保障公众安全的幕后重要活动组成部分。

相似文献

1
Behind the scenes in public health: Adverse events following immunization (AEFI) signal investigation in British Columbia.公共卫生幕后故事:不列颠哥伦比亚省免疫接种后不良事件(AEFI)信号调查
Can Commun Dis Rep. 2014 Dec 4;40(Suppl 3):24-30. doi: 10.14745/ccdr.v40is3a03.
2
Safety profile of - 17 years of GSK's passive post-marketing surveillance.葛兰素史克17年被动上市后监测的安全性概况。
Expert Rev Vaccines. 2020 Aug;19(8):771-779. doi: 10.1080/14760584.2020.1800458. Epub 2020 Aug 10.
3
Adverse events following immunization in Ontario's female school-based HPV program.安大略省基于学校的 HPV 计划中女性的疫苗接种后不良反应。
Vaccine. 2014 Feb 19;32(9):1061-6. doi: 10.1016/j.vaccine.2014.01.004. Epub 2014 Jan 15.
4
Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.预防接种后不良反应:尼日利亚 2017/2018 年麻疹疫苗接种运动的发现,2017/2018 年麻疹疫苗接种运动中的 AEFI 报告。
Vaccine. 2021 Nov 17;39 Suppl 3:C82-C88. doi: 10.1016/j.vaccine.2021.02.067. Epub 2021 Mar 11.
5
Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.中国 2010-2015 年免疫接种后不良反应事件国家监测报告死亡病例。
Vaccine. 2019 Feb 21;37(9):1182-1187. doi: 10.1016/j.vaccine.2019.01.009. Epub 2019 Jan 29.
6
Adverse Events Following Immunization in Brazil: Age of Child and Vaccine-Associated Risk Analysis Using Logistic Regression.巴西的疫苗接种后不良反应:使用逻辑回归分析儿童年龄和疫苗相关风险。
Int J Environ Res Public Health. 2018 Jun 1;15(6):1149. doi: 10.3390/ijerph15061149.
7
Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.1991年至1998年脊髓灰质炎疫苗不良事件监测:灭活脊髓灰质炎疫苗随后接种口服脊髓灰质炎疫苗的序贯接种方案的影响
Pediatrics. 2001 May;107(5):E83. doi: 10.1542/peds.107.5.e83.
8
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.免疫接种后安全性监测:疫苗不良事件报告系统(VAERS)——美国,1991 - 2001年
MMWR Surveill Summ. 2003 Jan 24;52(1):1-24.
9
Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.免疫接种后不良事件的常规监测是监测疫苗安全性的一项重要工具。
Hum Vaccin Immunother. 2015;11(1):91-4. doi: 10.4161/hv.34360. Epub 2014 Nov 1.
10
Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017.2011 年至 2017 年在中国广州进行的五联疫苗(DTaP-IPV/Hib 联合疫苗)上市后监测的安全性。
Int J Infect Dis. 2020 Oct;99:149-155. doi: 10.1016/j.ijid.2020.07.019. Epub 2020 Aug 12.

引用本文的文献

1
Adverse events following pediatric immunization in an Indian city.印度某城市儿童免疫接种后的不良事件。
Clin Exp Vaccine Res. 2021 Sep;10(3):211-216. doi: 10.7774/cevr.2021.10.3.211. Epub 2021 Sep 30.
2
Canada's Vaccine Vigilance Working Group.加拿大疫苗警戒工作组
Can Commun Dis Rep. 2014 Dec 4;40(Suppl 3):37-40. doi: 10.14745/ccdr.v40is3a05.
3
Vaccine vigilance in Canada: Is it as robust as it could be?加拿大的疫苗警戒:它是否已足够健全?
Can Commun Dis Rep. 2014 Dec 4;40(Suppl 3):2-6. doi: 10.14745/ccdr.v40is3a01.

本文引用的文献

1
Vaccine administration: preventing serious shoulder injuries.疫苗接种:预防严重肩部损伤
J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):102-3. doi: 10.1331/JAPhA.2013.13503.
2
A "needling" problem: shoulder injury related to vaccine administration.一个“针刺”问题:与疫苗接种相关的肩部损伤。
J Am Board Fam Med. 2012 Nov-Dec;25(6):919-22. doi: 10.3122/jabfm.2012.06.110334.
3
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project.结合欧洲的电子医疗数据库以实现大规模药物安全监测:EU-ADR 项目。
Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1-11. doi: 10.1002/pds.2053. Epub 2010 Nov 8.
4
Shoulder injury related to vaccine administration (SIRVA).疫苗接种相关肩部损伤(SIRVA)。
Vaccine. 2010 Nov 29;28(51):8049-52. doi: 10.1016/j.vaccine.2010.10.005. Epub 2010 Oct 16.
5
The sudden infant death syndrome.婴儿猝死综合征
N Engl J Med. 2009 Aug 20;361(8):795-805. doi: 10.1056/NEJMra0803836.
6
Vaccination greatly reduces disease, disability, death and inequity worldwide.疫苗接种在全球范围内极大地减少了疾病、残疾、死亡和不公平现象。
Bull World Health Organ. 2008 Feb;86(2):140-6. doi: 10.2471/blt.07.040089.
7
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.过敏反应:免疫接种安全性数据的病例定义及数据收集、分析与呈现指南
Vaccine. 2007 Aug 1;25(31):5675-84. doi: 10.1016/j.vaccine.2007.02.064. Epub 2007 Mar 12.
8
Vaccination-related shoulder dysfunction.疫苗接种相关的肩部功能障碍。
Vaccine. 2007 Jan 8;25(4):585-7. doi: 10.1016/j.vaccine.2006.08.034. Epub 2006 Sep 8.